Half Hemolysis Rate (CH50/HC50) Testing: Principles, Methods, and Applications

Half hemolysis rate testing quantifies the point at which 50% of red blood cells undergo lysis, providing a critical measure of blood compatibility for medical devices, biomaterials, and pharmaceuticals, as well as a sensitive indicator of serum complement activity. This article explains the scientific principles, standard test methods, sample types, and practical applications of 50% hemolysis rate (CH50/HC50) evaluation performed by accredited third-party laboratories.

Technical Overview

The half hemolysis rate, also referred to as the 50% hemolysis endpoint, describes the condition under which exactly half of the red blood cells (erythrocytes) in a standardized suspension are lysed. Because lysed erythrocytes release intracellular hemoglobin into the surrounding medium, the degree of hemolysis can be quantified precisely by measuring the absorbance of the released hemoglobin, typically at a wavelength of 540 to 545 nm using a UV-Vis spectrophotometer.

The concept is applied in two principal contexts. In the first context, the hemolysis rate evaluates the blood-damaging potential of medical devices, biomaterials, and parenteral products in accordance with biocompatibility standards such as ISO 10993-4 and its Chinese counterpart GB/T 16886.4. In the second context, the half hemolysis endpoint defines the CH50 value (50% complement hemolytic activity), which is the reciprocal of the serum dilution that lyses 50% of a standardized suspension of antibody-sensitized sheep erythrocytes. CH50 testing is a classical functional assay of the classical complement pathway and is interpreted using the Von Krogh equation.

A closely related parameter is the HC50 value, defined as the concentration of a test substance (for example, a surfactant or drug candidate) that produces 50% hemolysis under controlled in vitro conditions. Together, these measurements provide quantitative, reproducible, and clinically meaningful information about interactions between test articles and blood components.

Testing Samples

Blood and Serum Specimens

Fresh anticoagulated rabbit blood is the specimen most commonly specified by GB/T 16886.4 and related methods for device hemolysis testing, because rabbit erythrocytes demonstrate sensitivity comparable to human erythrocytes. Human blood samples collected with heparin or citrate anticoagulants, as well as human or animal serum specimens, are used for complement CH50 functional assays and for pharmaceutical hemolysis studies.

Medical Devices and Blood-Contacting Products

• Intravascular catheters, guidewires, and stents
• Blood bags, transfusion and infusion sets, and syringes
• Hemodialyzers, extracorporeal circuit tubing, and oxygenator membranes
• Artificial heart valves, vascular grafts, and stent grafts
• Wound dressings, hemostatic agents, and surgical implants

Biomaterials, Drugs, and Chemicals

• Polymeric, metallic, and ceramic biomaterials in raw or processed form
• Surface coatings and leachables extracted from finished devices
• Injectable formulations, contrast agents, and nanomedicine products
• Surfactants, excipients, and cosmetic ingredients evaluated for HC50

Testing Items

Typical test items offered by accredited third-party laboratories include:

• Total hemolysis rate (%) of medical device extracts or materials in direct contact with blood
• HC50 determination: the concentration of a test substance causing 50% hemolysis
• CH50 (50% complement hemolytic activity) in serum, reported in U/mL
• Alternative pathway complement activity (AH50) as a complementary assessment
• Free plasma hemoglobin and residual erythrocyte counts as supporting indicators
• Comparison of test articles against negative controls (such as saline) and positive controls (such as distilled water or Triton X-100)

Testing Methods

Direct Contact Method

The test article is placed in direct contact with diluted anticoagulated blood and incubated, typically at 37°C for a defined period. After centrifugation, the absorbance of the supernatant is measured at approximately 545 nm. The hemolysis rate is calculated by comparing the absorbance of the test sample with that of the negative and positive controls: Hemolysis rate (%) = (OD test − OD negative control) / (OD positive control − OD negative control) × 100.

Indirect Extract Method

For devices or materials that cannot be tested in direct contact, an extract is prepared using a specified vehicle such as physiological saline or serum-free culture medium under standardized extraction conditions (for example, 37°C for 24 hours, or accelerated conditions justified by the intended use). The extract is then incubated with diluted blood, and hemoglobin release is quantified spectrophotometrically.

CH50 Complement Hemolytic Assay

Sheep erythrocytes are sensitized with specific antibody to form EA cells. Serial dilutions of test serum are mixed with a fixed quantity of EA cells and incubated to allow complement-mediated lysis. After centrifugation, the hemoglobin released into the supernatant is measured photometrically. The percentage of hemolysis in each tube is plotted according to the Von Krogh transformation, and the serum dilution corresponding to 50% lysis is determined. The reciprocal of this dilution defines the CH50 value in units per milliliter.

Spectrophotometric Quantification of Hemoglobin

Released hemoglobin may be quantified directly by absorbance measurement or converted to a stable derivative, such as cyanmethemoglobin using Drabkin's reagent, to improve accuracy and reproducibility. Standard curves prepared from purified hemoglobin allow absolute quantification when required.

Reference Standards and Acceptance Criteria

• ISO 10993-4 / GB/T 16886.4: Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood
• ASTM F756: Standard practice for evaluation of hemolytic properties of materials
• YY/T 0127 series for dental material hemolysis evaluation
• Commonly cited acceptance criterion: hemolysis rate below 5% is generally regarded as non-hemolytic for blood-contacting devices

Applications

Half hemolysis rate testing supports safety evaluation and regulatory submission across multiple industries:

• Medical device biocompatibility: Hemocompatibility assessment is a regulatory expectation for all devices contacting circulating blood, including cardiovascular implants and extracorporeal circuits, forming part of ISO 10993-based biological evaluation files for registrations in China, the European Union, the United States, and other markets.
• Pharmaceutical development: Injectable drug candidates and formulations are screened for their hemolytic potential to establish safe intravenous administration, and HC50 values guide formulation optimization.
• Biomaterials research: Novel polymers, coatings, and nanomaterials are compared for erythrocyte compatibility during early-stage material selection.
• Clinical immunology: CH50 assays assist in diagnosing complement deficiencies and monitoring complement activation in immune complex diseases; markedly reduced CH50 may indicate deficiency of classical pathway components.
• Cosmetics and consumer products: Ingredients with potential for systemic exposure or mucosal contact are evaluated for cytolytic activity toward erythrocytes.
• Quality control: Batch release testing of blood-contacting consumables, such as transfusion sets and dialyzers, verifies consistent manufacturing quality.

FAQ

What hemolysis rate is considered acceptable for medical devices?

Under ISO 10993-4 and GB/T 16886.4 evaluation practice, a hemolysis rate below 5% is generally considered non-hemolytic and acceptable for blood-contacting devices, while results of 5% or above require justification, redesign, or additional hemocompatibility testing.

Why is rabbit blood commonly used in hemolysis testing?

Rabbit erythrocytes exhibit hemolytic sensitivity similar to human erythrocytes, rabbit blood can be obtained fresh and standardized under controlled conditions, and its use is widely established in recognized standards for device biocompatibility testing. Human blood may also be used when justified by the test protocol.

What is the difference between hemolysis rate and CH50?

The hemolysis rate expresses the percentage of erythrocytes lysed by a material or substance, evaluating the test article itself. CH50, by contrast, measures the functional activity of complement in a serum sample, defined as the dilution that lyses 50% of sensitized sheep erythrocytes; it is an immunological indicator rather than a material safety metric.

How is HC50 determined experimentally?

A concentration series of the test substance is incubated with a standardized erythrocyte suspension under controlled temperature and time conditions. Hemoglobin release is measured spectrophotometrically for each concentration, a dose-response curve is constructed, and the concentration producing 50% hemolysis is interpolated from the curve.

What controls are included in a valid hemolysis test?

Each assay includes a negative control, typically physiological saline or the extraction vehicle, expected to produce negligible lysis, and a positive control, typically distilled water or a detergent solution, expected to produce complete lysis. Results are only valid when both controls perform within predefined acceptance limits.

How should samples be submitted for testing?

Finished devices or representative material coupons should be supplied in sterile, clean condition in sufficient quantity for both test and control preparations. Extractable device portions are typically tested at a standardized surface-area-to-extraction-medium ratio, for example 3 cm² per mL or 0.2 g per mL as appropriate to the product geometry, following the requirements of the selected test protocol.